Effects of resistance‐associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs
Hepatology Research2019Vol. 49(11), pp. 1275–1285
Citations Over TimeTop 25% of 2019 papers
Goki Suda, Megumi Kimura, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto
Abstract
When undertaking retreatment for genotype 2a HCV-infected patients who fail to respond to DAAs, the optimized retreatment should be chosen according to the sensitivity of the emerging RAVs to anti-HCV drugs.
Related Papers
- → Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection(2014)1,191 cited
- → Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China(2017)26 cited
- → Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine(2016)7 cited
- → Possible Involvement of the NS3 Protein of Hepatitis C Virus in Hepatocarcinogenesis: Its Interaction with the p53 Tumor Suppressor(2003)3 cited
- → Resistance to Direct-Acting Antiviral Agents in Treatment of Hepatitis C Virus Infections(2017)1 cited